GGTI-2166, with the CAS number 478908-51-9, is a small molecule inhibitor primarily known for its role in research related to cancer and other diseases. It functions as a selective inhibitor of geranylgeranyltransferase I (GGTase I), an enzyme involved in the post-translational modification of proteins through the addition of geranylgeranyl groups. This modification is crucial for the proper functioning of various signaling proteins, including some involved in oncogenic pathways. By inhibiting GGTase I, GGTI-2166 can disrupt these signaling pathways, potentially leading to reduced cell proliferation and increased apoptosis in cancer cells. The compound has been studied for its effects on various cancer types, showcasing its potential as a therapeutic agent. Additionally, GGTI-2166's specificity for GGTase I over other prenyltransferases makes it a valuable tool in understanding the biological roles of protein prenylation. As with many experimental compounds, further research is necessary to fully elucidate its pharmacological properties and therapeutic potential.

GGTI-2166 is a geranylgeranyl transferase I inhibitor.  GGTI-2166 inhibit the pOC formation induced by RANKL or TNF-alpha in cultures of both mouse marrow-derived macrophage-colony-stimulating factor (M-CSF) dependent monocytes (MD cells) and the mouse monocyte cell line RAW 264.7 (RAW cells). GGTI-2166 inhibited TRAP activity induced by RANKL or TNF-alpha in both cell cultures and prevented the incorporation of [3H]all-trans geranylgeraniol into prenylated proteins in RAW cells.

GGTI-2166

478908-51-9: GGTI-2166, with the CAS number 478908-51-9, is a small molecule inhibitor primarily known for its role in research related to cancer and other diseases. It functions as a selective inhibitor of geranylgeranyltransferase I (GGTase I), an enzyme involved in the post-translational modification of proteins through the addition of geranylgeranyl groups. This modification is crucial for the proper functioning of various signaling proteins, including some involved in oncogenic pathways. By inhibiting GGTase I, GGTI-2166 can disrupt these signaling pathways, potentially leading to reduced cell proliferation and increased apoptosis in cancer cells. The compound has been studied for its effects on various cancer types, showcasing its potential as a therapeutic agent. Additionally, GGTI-2166's specificity for GGTase I over other prenyltransferases makes it a valuable tool in understanding the biological roles of protein prenylation. As with many experimental compounds, further research is necessary to fully elucidate its pharmacological properties and therapeutic potential.

GGTI-2166, a geranylgeranyl transferase I inhibitor, blocks pOC formation and TRAP activity in MD and RAW 264.7 cells, and hinders protein prenylation.

CAS 478908-51-9

GGTI-2166

GGTI-2166

Ref: TM-T69205